Across TCGA pan-cancer cohorts, RAD51C mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAD51C data layer compared with 24 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAD51C mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAD51C expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
HNSC, LUAD, and LSCC are the cancer types where RAD51C mass-spec protein most reproducibly stratifies survival.